Patent · US Active

Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors

US9695180B2 · kind B2 · utility

24Cited by

5References

53Claims

0Family size

Assignee

Incyte Corporation · US

Inventors

Liangxing Wu · Wilmington, US
Joel R. Courter · Glen Mills, US
Chunhong He · Boothwyn, US
Jingwei Li · Beijing, CN
Liang Lu · Hockessin, US
Yaping Sun · Lexington, US
Xiaozhao Wang · Readington, US
Wenqing Yao · Kennett Square, US
Colin Zhang · Ambler, US
Jincong Zhuo · Boothwyn, US

Key dates

Filing date	Jul 9, 2015
Grant date	Jul 4, 2017
Priority date	—
Expiry date	Aug 26, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.